{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:42:48Z","timestamp":1793742168728,"version":"4.6.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>MGMT promoter methylation is a critical predictive biomarker in high-grade gliomas (HGG), but its assessment currently relies on invasive tissue sampling. We aimed to develop an explainable, modality-adaptive, and calibrated radiomics model for non-invasive prediction of MGMT promoter methylation using multi-center MRI data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pre-operative MRI from the UCSF-PDGM and UPENN-GBM cohorts was analyzed using radiomics extracted from intratumoral and peritumoral regions. Conventional (T1, T2, FLAIR) and advanced (DWI\/ADC, ASL) MRI sequences were included. A novel modality-adaptive framework was implemented, allowing the model to automatically ignore advanced modalities when unavailable. After feature ranking and redundancy reduction, six machine-learning classifiers were optimized and Platt-calibrated. Model performance was evaluated on a held-out test set using ROC metrics, calibration assessment, and Decision Curve Analysis (DCA). Feature contributions were interpreted using SHAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The top-performing LightGBM model, trained on the 500 most important radiomic features, achieved an AUC of 0.67, recall of 0.90, and accuracy of 0.72 on the independent test set. The model demonstrated strong sensitivity for identifying methylated tumors, minimizing false-negative predictions. Calibration improved clinical net benefit across a range of threshold probabilities on DCA. Feature attribution analysis revealed balanced contributions from conventional and advanced MRI modalities, with texture and intensity-based descriptors being most influential. Notably, low-frequency FLAIR wavelet intensity features were associated with unmethylated tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This explainable, modality-adaptive radiomics model identified biologically consistent MGMT-related imaging patterns and demonstrated decision-analytic value for clinical risk stratification. The framework supports real-world applicability in heterogeneous imaging environments. Future work should focus on external validation and integration with clinical and molecular biomarkers to further enhance predictive performance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1731258","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:39:35Z","timestamp":1767940775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Explainable, modality-adaptive radiomics for MGMT methylation prediction in high-grade glioma: a decision-curve analysis study"],"prefix":"10.3389","volume":"15","author":[{"given":"Rafail C.","family":"Christodoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Vamvouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Pitsillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E.","family":"Solomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis F.","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/jpm13060999","article-title":"MGMT promoter methylation: prognostication beyond treatment response","volume":"13","author":"Ashkan","year":"2023","journal-title":"JPM"},{"key":"B2","doi-asserted-by":"publisher","first-page":"997\u20131003","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"n Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/diagnostics15030251","article-title":"Virtual biopsy for the prediction of MGMT promoter methylation in gliomas: A comprehensive review of radiomics and deep learning approaches applied to MRI","volume":"15","author":"Leone","year":"2025","journal-title":"Diagnostics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1118\/1.4948668","article-title":"MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas","volume":"43","author":"Korfiatis","year":"2016","journal-title":"Med Phys"},{"key":"B6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-018-4114-2","article-title":"Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis","volume":"18","author":"Han","year":"2018","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03933-1","article-title":"Radiomics for precision medicine in glioblastoma","volume":"156","author":"Aftab","year":"2022","journal-title":"J Neurooncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/eng6100262","article-title":"Artificial intelligence in glioma diagnosis: A narrative review of radiomics and deep learning for tumor classification and molecular profiling across positron emission tomography and magnetic resonance imaging","volume":"6","author":"Christodoulou","year":"2025","journal-title":"Eng"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10594-x","article-title":"Quality assessment of the MRI-radiomics studies for MGMT promoter methylation prediction in glioma: a systematic review and meta-analysis","volume":"34","author":"Doniselli","year":"2024","journal-title":"Eur Radiology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27533","DOI":"10.1038\/s41598-025-08608-9","article-title":"Prediction of MGMT methylation status in glioblastoma patients based on radiomics feature extracted from intratumoral and peritumoral MRI imaging","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"B12","volume-title":"The university of california San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) (Version 5)","author":"Calabrese","year":"2022"},{"key":"B13","volume-title":"Multi-parametric magnetic resonance imaging (mpMRI) scans for","author":"Bakas","year":"2021"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1145\/3292500","article-title":"Optuna: A next-generation hyperparameter optimization framework","author":"Akiba","year":"2019","journal-title":"arXiv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: A novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"B16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s40644-024-00817-1","article-title":"Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions","volume":"24","author":"Yu","year":"2024","journal-title":"Cancer Imaging"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrae007","article-title":"Radiomics for predicting MGMT status in cerebral glioblastoma: comparison of different MRI sequences","volume":"65","author":"Zheng","year":"2024","journal-title":"J Radiat Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.09.049","article-title":"An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging","volume":"49","author":"Drabycz","year":"2010","journal-title":"NeuroImage"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2950","article-title":"Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma","volume":"33","author":"Carrillo","year":"2012","journal-title":"AJNR Am J Neuroradiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100583","DOI":"10.1016\/j.eij.2024.100583","article-title":"Towards precision medicine in Glioblastoma: Unraveling MGMT methylation status in glioblastoma using adaptive sparse autoencoders","volume":"29","author":"Fazal","year":"2025","journal-title":"Egyptian Inf J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1439\u201345","DOI":"10.3174\/ajnr.A5711","article-title":"Clinically relevant imaging features for MGMT promoter methylation in multiple glioblastoma studies: A systematic review and meta-analysis","volume":"8","author":"Suh","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/cancers16101906","article-title":"\u2018The reports of my death are greatly exaggerated\u2019\u2014Evaluating the effect of necrosis on MGMT promoter methylation testing in high-grade glioma","volume":"16","author":"Satgunaseelan","year":"2024","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/cancers15051384","article-title":"Peritumoral ADC values correlate with the MGMT methylation status in patients with glioblastoma","volume":"15","author":"Ladenhauf","year":"2023","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1731258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:39:36Z","timestamp":1767940776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1731258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1731258"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1731258","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1731258"}}